Video Insights
Advertisement
Dr. Atrash reviews real-world data on four selinexor-based triplets used in the treatment of relapsed or refractory myeloma.
At EHA 2024, Dr. Santini shares data on luspatercept and imetelstat in patients with MDS and anemia.
Dr. Garcia-Manero discusses the latest updates from the COMMANDS trial.
Jamile Shammo, MD, leads a roundtable discussion on the effect of molecular data incorporation and goals in treatment.
Dr. David Swoboda discusses the importance of MDS World Awareness Day and what makes MDS unique compared to other diseases.
The expert panel led by Jamile Shammo, MD, tells how trial data and their clinical experiences inform their use of the agent.
Advertisement
Drs. Rossi and Khouri discuss two presentations on the effects of selinexor exposure on CAR-T outcomes in multiple myeloma.
Stefan K. Barta, MD, MS, discusses his recent study on central nervous system relapse in T-cell lymphomas.
Bilal Abid, MD, describes how to approach sequencing pirtobrutinib after CAR-T therapy.
The positive safety profile of this bispecific antibody makes it well-suited for combination with other treatments.
Adam Kittai, MD, discusses sequencing pirtobrutinib and CAR-T in the management of CLL with Richter transformation.
Dr. Abid describes when he uses bispecifics versus CAR-T in his practice at the University of Texas Health Science Center.
The farnesyltransferase inhibitor tipifarnib achieved an ORR of 40% and a median duration of response of 3.7 months.
The PETAL Consortium at the Jain Lab integrates AI-informed digital interface as a tool to facilitate clinical decisions.
Dr. Garcia-Manero discussed luspatercept, a first-in-class drug for patients with low-risk MDS and anemia.
The newer agents have distinguished themselves especially by having safety profiles superior to ibrutinib.
Dr. Rogers debated against Inhye Ahn, MD, on whether therapy with Bruton tyrosine kinase inhibitors can be discontinued.
Dr. Coombs discussed time limited therapies and the phase III AMPLIFY trial of acalabrutinib plus venetoclax in CLL.
COMMANDS is the first trial to perform a head-to-head comparison of luspatercept against an erythropoiesis-stimulating agent.
An expert on myelofibrosis comments on promising results from current trials and on the need for useful clinical biomarkers.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.